170 related articles for article (PubMed ID: 37992270)
21. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
[TBL] [Abstract][Full Text] [Related]
22. The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
Hamieh L; Beck RL; Le VH; Hsieh JJ
Clin Genitourin Cancer; 2020 Aug; 18(4):252-257.e2. PubMed ID: 32291161
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
24. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.
Lalani AA; Xie W; Braun DA; Kaymakcalan M; Bossé D; Steinharter JA; Martini DJ; Simantov R; Lin X; Wei XX; McGregor BA; McKay RR; Harshman LC; Choueiri TK
Eur Urol Oncol; 2020 Jun; 3(3):372-381. PubMed ID: 31562048
[TBL] [Abstract][Full Text] [Related]
25. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
26. Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System.
Kushnir I; Basappa NS; Ghosh S; Lalani AA; Hansen AR; Wood L; Kollmannsberger CK; Heng DYC; Bjarnason GA; Soulières D; Dawe DE; Tanguay S; Breau RH; Pouliot F; Kapoor A; Graham J; Reaume MN
Clin Genitourin Cancer; 2021 Dec; 19(6):521-530. PubMed ID: 34158246
[TBL] [Abstract][Full Text] [Related]
27. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
28. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract][Full Text] [Related]
29. Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors.
Johnston H; Deal AM; Morgan KP; Patel B; Milowsky MI; Rose TL
Clin Genitourin Cancer; 2023 Jun; 21(3):357-365. PubMed ID: 37012148
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular profile of contemporary treatments of renal cell carcinoma: A single-center prospective study.
Lee K; Lindenfeld L; Echevarria M; Hsu J; Wong FL; Narayan HK; Lau C; Cai L; Pal SK; Armenian SH; Rhee JW
Int J Cardiol; 2023 Jun; 380():40-46. PubMed ID: 36958393
[TBL] [Abstract][Full Text] [Related]
31. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.
Pal S; Gong J; Mhatre SK; Lin SW; Surinach A; Ogale S; Vohra R; Wallen H; George D
BMC Cancer; 2019 Jun; 19(1):548. PubMed ID: 31174493
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Basso U; Procopio G; Fornarini G; Massari F; Bearz A; Fratino L; Milella M; Bassanelli M; Ermacora P; Bimbatti D; Verzoni E; Rizzo M; Porta C
Oncology; 2021; 99(12):747-755. PubMed ID: 34583356
[TBL] [Abstract][Full Text] [Related]
33. The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma.
Bersanelli M; Buti S; Rizzo M
Expert Rev Anticancer Ther; 2021 Apr; 21(4):401-412. PubMed ID: 33287612
[No Abstract] [Full Text] [Related]
34. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
Albiges L; Choueiri T; Escudier B; Galsky M; George D; Hofmann F; Lam T; Motzer R; Mulders P; Porta C; Powles T; Sternberg C; Bex A
Eur Urol; 2015 Jan; 67(1):100-110. PubMed ID: 24841777
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis.
Araujo DV; Wells JC; Hansen AR; Dizman N; Pal SK; Beuselinck B; Donskov F; Gan CL; Yan F; Tran B; Kollmannsberger CK; de Velasco G; Yuasa T; Reaume MN; Ernst DS; Powles T; Bjarnason GA; Choueiri TK; Heng DYC; Dudani S
J Geriatr Oncol; 2021 Jun; 12(5):820-826. PubMed ID: 33674246
[TBL] [Abstract][Full Text] [Related]
36. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
37. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.
Chehrazi-Raffle A; Meza L; Alcantara M; Dizman N; Bergerot P; Salgia N; Hsu J; Ruel N; Salgia S; Malhotra J; Karczewska E; Kortylewski M; Pal S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688021
[TBL] [Abstract][Full Text] [Related]
38. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
[TBL] [Abstract][Full Text] [Related]
39. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.
Ravi P; Mantia C; Su C; Sorenson K; Elhag D; Rathi N; Bakouny Z; Agarwal N; Zakharia Y; Costello BA; McKay RR; Narayan V; Alva A; McGregor BA; Gao X; McDermott DF; Choueiri TK
JAMA Oncol; 2020 Oct; 6(10):1606-1610. PubMed ID: 32469396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]